The case for & against
Bull & Bear analysis
Bearish
CytoMed Therapeutics Ltd (GDTC) is an emerging player in the biotechnology sector, focusing on developing innovative immunotherapy treatments leveraging its proprietary technology in targeted immune treatments. Situated in a niche segment of advanced cancer therapies, the company is poised to capitalize on the growing demand for personalized medicine, utilizing immunotherapy approaches to enhance patient outcomes. Its collaboration with notable institutions, such as Universiti Malaya for clinical trials, reflects its commitment to advancing its product pipeline within this transformative therapeutic landscape.
Bull says
- ↑Phase I clinical trial shows promising immunotherapy efficacy
- ↑High growth factor suggests strong oncology expansion opportunity
- ↑Robust quality score reflects solid financial and operational strength
- ↑High liquidity ensures funding for ongoing trials and R&D
- ↑Favorable sensitivity to oil prices and interest rates supports stability
- ↑Upcoming trial milestones could catalyze significant valuation upside
Bear says
- ↓Negative earnings yield and low profitability signal poor returns
- ↓High leverage raises debt service and operational risk
- ↓Average analyst target of $0.65 vs $0.99 current implies downside
- ↓Stock down 4.7% over last 10 days shows weak momentum
- ↓Elevated short interest underscores skepticism and downside pressure
- ↓Negative earnings revisions highlight growing analyst pessimism
Earnings Call · Q2 2025 · Mgmt. Guidance
Updated 11-15-2025bearish
Transcript signals
Bull points
- Our revenue increased by 100% to $156,000 for the 6 months ended 30 June 2025, starting to generate revenue from private blood banking services after acquiring the license and certain assets under our subsidiary in Malaysia.
Bear points
- We reported a net loss of $2.25 million in 2025, and net loss will be reduced to $1.44 million if the share-based payment, net currency exchange losses, the fair value losses on warrant liability and the costs associated with being a publicly listed company are excluded.
- a reduction of $105,000 in interest income from the placement of IPO proceeds in fixed deposit.
- we reported a net loss of $1.09 million in first half 2024 compared to net loss of $2.25 million in first half 2025. Net loss will be reduced to $1.44 million if the share-based payment, net currency action losses, the fair value losses on warrant liability, and the costs associated with being a public-listed company are excluded.
Read full transcript analysis ›